Managing TheTripleThreat™
70% of all nosocomial bloodstream infections occur in patients with central venous catheters.5 One in six CLABSIs are caused by urgent or serious antibiotic-resistant threats (Centers for Disease Control).8
In Canada alone, there are an estimated 137 infections and 34 deaths per day with $1.7B per year in incremental healthcare expenditure to treat these preventable infections.4
Breaking the cycle
Reduce the incidence of clots, microorganisms and biofilm formation with one simple solution.
KiteLock™ is transforming central venous access care by providing a powerful solution to maintain patency and by reducing the risk of bacterial colonization and biofilm formation within central venous access devices (CVADs).
Simply eliminating the risk of clots is no longer sufficient. Within seven days, CVADs can become colonized with microorganisms embedded in biofilm resulting in a potential source of life threatening infections.5
The only solution with the capability to eradicate biofilm, including strains of multi-drug resistant bacteria.6, 7
The Power of 3
Antimicrobial
Antibiofilm
Anticoagulation
- 4% Tetrasodium EDTA catheter lock solution
- Demonstrates statistically significant reduction of clinically relevant organisms by 87%2
- Powerful antimicrobial and antibiofilm solution and trusted anticoagulant
Clinical
Impact
Creating
Awareness
Cost
Efficient
CLINICAL IMPACT
KiteLock™ 4% Sterile Catheter Lock Solution directly addresses all three interrelated processes with its ability to reduce clot formation, prevent bacterial colonization and biofilm formation. In a human clinical trial, KiteLock™ demonstrated a statistically significant reduction of clinically relevant microorganisms by 87% (p = 0.02) compared to heparin in hemodialysis patients, as well as a good safety profile1. Microbiological studies showed eradication of both Gram+ and Gram- bacteria including MRSA and Pseudomonas, as well as Candida species, with associated biofilms2,3. Moreover, it is in line with Global Antibiotic Stewardship programs, as KiteLock™ is a non-antibiotic antimicrobial agent.
1. Kanaa, M et al. 2015. Cathasept line lock and microbial colonization of tunneled hemodialysis catheters: A multicentre randomized controlled trial. Am J Kidney Dis, 66(6):1015-1023.
2. Kite, P et al. 2004. Use of in vivo-generated biofilms from hemodialysis catheters to test the efficacy of a novel antimicrobial catheter lock for biofilm eradication in vitro. Journal of Clinical Microbiology, 42(7):3073-3076.
3. Percival, SL et al. 2005. Tetrasodium EDTA as a novel central venous catheter locking solution against biofilm. Injection Control and Hospital Epidemiology, 26(6):515-519.
CREATING AWARENESS
Why do we care about bacteria presence within the CVAD lumen?
A. Risk of CLABSI
Ryder MA, 2005. Catheter-related infections: It’s all about biofilm. Topics in Advanced Practice Nursing eJournal, 5(3).
B. Relevance to antibiotic stewardship
Kostakioti et al, 2013. Bacterial biofilms: Development, dispersal, and therapeutic strategies in the dawn of the postantibiotic era. Cold Spring Harbor Perspectives in Medicine, 3:a010306.
C. Complications nobody talks about
COST EFFICIENT
According to the US Center for Disease Control (CDC) in the US alone, over 200,000 patients per year develop CLABSI and as many as 40,000 of these cases result in death1. According to the World Health Organization (“WHO”), the US has an overall hospital-acquired infection (“HAI”) rate of 4.5% compared to 11.6% in Canada and 7.1% in Europe2. This data suggests that currently there are about 50,000 CLABSI with corresponding deaths of 12,500/year in Canada. Using the CDC estimates of $34,500-56,000 per case suggest a healthcare cost of $1.7 billion/year in Canada. This equates to 137 infections, 34 deaths and the unnecessary expenditure of $4.6 million each day on preventable infections in Canada alone.
1. O’Grady, NP et al; “Guidelines for the prevention of intravascular catheter-related infections, 2011.” The US Centers for Disease Control.
2. “The burden of healthcare-associated infection world-wide: a summary.” 2011, World Health Organization.
Extracted from third party market analysis – Christie Consulting Services (2013)
